Inflammatory Biomarkers and Bladder Cancer Prognosis: A Systematic Review
- 1 December 2014
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 66 (6), 1078-1091
- https://doi.org/10.1016/j.eururo.2014.07.033
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.govBMC Urology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Three differentiation states risk-stratify bladder cancer into distinct subtypesProceedings of the National Academy of Sciences of the United States of America, 2012
- FOXP3 and survival in urinary bladder cancerBJU International, 2011
- Statistical consideration for clinical biomarker research in bladder cancerUrologic Oncology, 2010
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaProceedings of the National Academy of Sciences of the United States of America, 2007
- The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladderBritish Journal of Cancer, 2006
- The case of the misleading funnel plotBMJ, 2006
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002